12.62
+9.45%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MoonLake Immunotherapeutics
From its filings with the US Securities and Exchange Commission
MoonLake Immunotherapeutics is based in Zug, Switzerland and is incorporated in Cayman Islands. Its shares trade on Nasdaq under the ticker MLTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $227.3m. At that date it held total assets of $424.4m and shareholders' equity of $304.5m.
We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
We currently develop SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. This group of diseases comprises our current target diseases, hidradenitis suppurativa (“HS”), psoriatic arthritis (“PsA”), axial spondyloarthritis (“axSpA”), palmoplantar pustulosis (“PPP”), and several other inflammatory conditions, including psoriasis (“PsO”). Our current target diseases affect millions of people worldwide, and we believe there is a need for improved treatment options. We believe that SLK has a differentiated mechanism of action and that its purposefully designed molecular characteristics, including its small size and its albumin binding site, facilitate deep tissue penetration in the skin and joints. We envision SLK as a key therapeutic alternative in our initial target indications and potentially in multiple other IL-17 driven inflammatory conditions.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Oct 2020
- Employees
- 130
- Website
- moonlaketx.com ↗
- Head office
- DORFSTRASSE 29, ZUG, V8, 6300
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Simon SturgeIndependent Chairman of the Board$430,644
- Dr. Jorge Santos Da SilvaChief Executive Officer, Director, since 2022$4.5m
- Mr. Matthias BodenstedtChief Financial Officer$5.7m
- Dr. Kristian ReichChief Scientific Officer$4.6m
- Mr. Spike LoyIndependent Director$35,103
- Ms. Catherine MoukheibirIndependent Director$411,799
- Dr. Andrew PhillipsIndependent Director$407,365
- Dr. Ramnik XavierIndependent Director$422,884
- Dr. Atif KhanDirector - Strategic Planning and Projects, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MoonLake Immunotherapeutics has 130 employees in the Health Care sector with a focus on biotechnology.
- SLK targets inflamed tissues with enhanced enrichment in deep skin and joints for inflammatory diseases.
- The company's clinical-stage biopharmaceutical focus on immunologic diseases includes inflammatory skin and joint conditions.
Weaknesses
- MoonLake Immunotherapeutics has only 20 full-time employees despite having 130 total employees.
- The company's IPO was on 20 October 2020, indicating a relatively recent market entry.
- The firm's product SLK is still in clinical development without commercialization yet.
Opportunities
- The Health Care sector offers growth potential for biotechnology companies developing immunologic disease treatments.
- SLK's unique targeting of IL-17A and IL-17F dimers presents a novel therapeutic approach.
- The increasing prevalence of inflammatory skin and joint diseases creates market demand for new treatments.
Threats
- Competition in the Health Care sector from established biotechnology firms remains a challenge.
- Regulatory hurdles for clinical-stage biopharmaceutical companies could delay product approval.
- Market volatility in the biotechnology industry may affect investor confidence and funding.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.